Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

ConclusionsThe results of this interim analysis suggest that idarucizumab is safe and effective for the reversal of dabigatran in Japanese patients in a real-world setting, and support the continued use of idarucizumab.Trial RegistrationClinicalTrials.gov identifier, NCT02946931.

Source: Cardiology and Therapy - March 8, 2020 Category: Cardiology Source Type: research